Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 19, 2007

Glenmark Buys Rights to Two mAbs from Chromos

  • Glenmark Pharmaceuticals completed the purchase of two NBEs from Chromos Molecular Systems. CHR-1103 and CHR-1201 are humanized mAbs.

    Under the terms of the transaction, Glenmark bought all rights to the products as well as rights to use Chromos' ACE System technology for cell-line development for use with respect to CHR-1103 and CHR-1201. Glenmark holds the worldwide rights for further development, registration, and commercialization of these products.

    CHR-1103 and CHR-1201 are part of a validated class of drugs known as SAMIs, or selective adhesion molecule inhibitors. CHR-1103 is an anti-inflammatory agent with a novel mechanism of action, being developed initially to treat acute multiple sclerosis. Glenmark plans to initiate Phase I trials in 2008.

    CHR-1201 is an antithrombolytic, which Glenmark plans to develop initially to treat acute stroke. The company expects to start Phase I on CHR-1201 by March 2009.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »